RNA Supply Chain Resources

  1. Mastering mRNA Manufacturing: A Focus on Raw Materials & Supply Assurance 10/23/2024

    Rapid advancements in mRNA-based therapeutic development have underscored the role of raw material quality and supply chain management in ensuring their successful production.

  2. Key Challenges for CRISPR In Clinical Development 2/28/2023

    Learn how to approach CRISPR cell and gene therapy development challenges, such as regulatory hurdles, ensuring consistency, finding qualified and experienced staff, and obtaining GMP-Grade reagents.

  3. Reduce Contamination Risks When Storing Synthetic DNA 10/30/2023

    An alternative to traditional polyethylene bags is offering cell and gene therapy manufacturers a solution to contamination concerns regarding DNA or RNA fragments.

  4. Transitioning From Using RUO To cGMP Chemicals For Clinical Trials 10/17/2023

    Learn about the common challenges and risks associated with accelerating your molecule's timeline from lab to clinic, along with important supply chain considerations for emerging biopharma companies.

  5. Uninterrupted Supply To Meet Demand 1/23/2024

    Explore a solution for biopharmaceutical companies concerned about the risks an increase in campaign volume can pose to their production timeline.

  6. The Key To Improving Global Supply Chain Resilience 6/10/2024

    Explore the past, present, and future of supply chain security, ways the biopharma industry can secure supply chains and minimize risks, and more.

  7. Delivering Global Media Manufacturing Consistency Through Site-To-Site Equivalency 7/8/2024

    Explore a program focused on achieving process consistency through risk mitigation in four key areas: raw materials sourcing, equipment, manufacturing processes, and finished product testing.

  8. Optimization Of Transient Transfection Of MSCs With Plasmid DNA Or mRNA 11/1/2022

    Read through the results of our efforts to produce an optimal protocol for the transient transfection of hMSCs with pDNA or mRNA using non-viral means.

  9. Pre-Banking And Avoiding Manufacturing Challenges For GMP Plasmids Containing Unstable Sequence Regions 4/21/2021

    Ensuring consistent replication and proper retention of plasmid DNA sequence is vital to the economics and efficiency in generating starting materials used for production of AAV delivered gene therapy and mRNA vaccines and therapeutics.

  10. Where Can Novel Non-Viral Polymeric Delivery Agents Take Us? 1/18/2023

    Explore ongoing work to harness different types of HDR templates in order to build cutting-edge systems with the potential to enable point-of-care cell and gene therapy manufacture.